In advanced CKD, ACEis or ARBs reduce kidney failure vs. placebo or non-RAAS inhibitors at 34 mo.

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-10-01 DOI:10.7326/ANNALS-24-02169-JC

Carlos E Aguilar Bolona, Wolfgang C Winkelmayer

引用次数: 0

Abstract

Source citation: Ku E, Inker LA, Tighiouart H, et al. Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for advanced chronic kidney disease: a systematic review and retrospective individual participant-level meta-analysis of clinical trials. Ann Intern Med. 2024;177:953-963. 38950402.

查看原文本刊更多论文

对于晚期 CKD 患者，与安慰剂或非 RAAS 抑制剂相比，ACEis 或 ARB 可在 34 个月时减少肾衰竭。

来源引用：Ku E, Inker LA, Tighiouart H, et al. 血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂治疗晚期慢性肾脏病：临床试验的系统综述和个人参与者水平的回顾性荟萃分析。Ann Intern Med.2024;177:953-963.38950402.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.